$ABEO
Abeona Therapeutics Inc
PRICE
$4.38 ▼-4.783%
Last Close
VOLUME
111,531
DAY RANGE
4.5 - 4.81
52 WEEK
0.1303 - 6.13
Key Metrics
Market Cap
28.38 M
Beta
2.13
Avg. Volume
273.45 K
Shares Outstanding
5.95 M
Yield
0%
Public Float
0
Next Earnings Date
2022-11-14
Next Dividend Date
Company Information
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.
CEO: Joao Siffert
Website: abeonatherapeutics.com
HQ: 1330 Avenue of the Americas Fl 33 New York, 10019-5442 New York
Related News